Katja Sockel, MD, University Hospital Carl Gustav Carus Dresden, Dresden, Germany, comments on factors to consider when selecting patients with myelofibrosis (MF) for allogeneic stem cell transplantation (alloSCT). Allogeneic stem cell transplantation is the only curative treatment option for MF, but careful patient selection is crucial due to the associated risks. Disease risk factors, including high molecular risk markers such as multi-hit TP53 and RAS pathway mutations, help identify patients who would benefit from transplantation. The myelofibrosis transplant scoring system (MTSS) incorporates clinical and molecular factors to predict overall and treatment-related survival after transplantation. Ultimately, the decision to undergo transplantation should also consider the patient’s preferences. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
